Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Strides Pharma Science - Steady quarter; growth to pick up - ICICI Securities

Posted On: 2020-10-30 08:23:36


Strides Pharma Science (Strides) reported a healthy Q2FY21 performance largely in-line with our estimates. Revenue grew 11.0% YoY to Rs7.9bn (I-Sec: Rs7.9bn) with growth across geographies, EBITDA margin declined 70bps to 19.8% (I-Sec: 20.2%) and adjusted PAT declined 7.5% YoY to Rs498mn (I-Sec: Rs554mn). US grew 8.0% QoQ to US$54mn supported by new launches and growth from its own front end. Other markets (EU, EM and institutional) continued to scale-up. We believe US market would grow 9.8% CAGR over FY20-FY23E and company's consolidated EBITDA margin would sustain levels around 20-21%. Minimal capex requirement and healthy operational performance would help in generating FCFF of ~Rs13bn over FY21E-FY23E. Retain BUY.

- Growth across geographies: US revenues improved 8.0% QoQ to US$54mn led by new launches and ~25% growth from its own front end which now contributes ~85% of total US sales. Growth has reduced in the current quarter owing to price erosion in the business and subdued demand for few products. We expect quarterly revenue run-rate to increase to ~US$60-65mn in coming quarters driven by new launches from several products that are pending approval. Supplies to Arrowtex in Australia were impacted with shutdown of its dedicated plant due to COVID-19, however, it has become fully operational now. Overall, other regulated markets grew 7.5% YoY. Africa reported a growth of 117% YoY (+20.6% QoQ). Institutional business grew 18.0% YoY (-13.3% QoQ). The regulated markets (US and EU) would be the key geographies for sustainable growth.

- Margin to sustain at 20-21%: EBITDA margin improved 50bps QoQ to 19.8% driven by operating leverage in the US market where growth from own front end was strong. Gross margin was flattish QoQ but improved 290bps YoY to 61.1% better than estimated 60%. We expect scale up in US business to provide additional operating leverage from the current levels that would be offset by investments towards future product pipeline. Hence, we expect the company to report EBITDA margin of 20-21% in FY21E-FY23E with gross margin of 60-61%.

- Outlook: We expect a 9.8% CAGR in US sales over FY20-FY23E led by 10-15 new launches every year and improving market share and EU to grow at 11.6% over FY20-FY23E with entry in newer markets and new product launches. Overall, expect revenue and earnings to CAGR at 13.3% and 59.0% respectively over FY20-FY23E. Expect return ratios to remain muted with continuous investments in Stelis Biopharma which that would turn profitable in H2FY22.

- Valuations and risks: We marginally revise our estimates to reflect current quarters performance. Maintain BUY on the stock with a revised target price of Rs776/share based on 17xSep'22E EPS (earlier: Rs773/share). Key downside risks: Regulatory hurdles, delay in new launches and pricing pressures in the US.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.689.6 as compared to the previous close of Rs. 672.5. The total number of shares traded during the day was 92354 in over 3571 trades.

The stock hit an intraday high of Rs. 702.8 and intraday low of 658.25. The net turnover during the day was Rs. 62833970.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019